ArticleGenome research2017
Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia.
Open access · bronzeAbstract read
In one paragraph
Article in Genome research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer's disease: review, recommendation, implementation and application.Molecular neurodegeneration · 2022Pooled it
- SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia.British journal of haematology · 2019Trial
- Presence of recombination hotspots throughout SLC6A3.PloS one · 2019Trial
- Co-mapping clonal and transcriptional heterogeneity in somatic evolution via GoT-Multi.Cell genomics · 2026Article
- Targeting WNK1 suppresses acute myeloid leukemia progression and enhances sensitivity to venetoclax.Frontiers in oncology · 2026Article
- Expression of Aldehyde Dehydrogenase 1A1 in Relapse-Associated Cells in Acute Myeloid Leukemia.Cells · 2025Review
- Stochastic modeling of single-cell gene expression adaptation reveals non-genomic contribution to evolution of tumor subclones.Cell systems · 2025Article
- Stochastic modelling of single-cell gene expression adaptation reveals non-genomic contribution to evolution of tumor subclones.bioRxiv : the preprint server for biology · 2024Article
- The molecular map of CLL and Richter's syndrome.Seminars in hematology · 2024Review
- ZAP-70 augments tonic B-cell receptor and CCR7 signaling in IGHV-unmutated chronic lymphocytic leukemia.Blood advances · 2024Article
- Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance.Experimental hematology & oncology · 2024Review
- Application and research progress of single cell sequencing technology in leukemia.Frontiers in oncology · 2024Review
- Single-cell genomics-based immune and disease monitoring in blood malignancies.Clinical hematology international · 2024Review
- Mouse models of chronic lymphocytic leukemia and Richter transformation: what we have learnt and what we are missing.Frontiers in immunology · 2024Review
- MNDA, a PYHIN factor involved in transcriptional regulation and apoptosis control in leukocytes.Frontiers in immunology · 2024Review
- De novo identification of expressed cancer somatic mutations from single-cell RNA sequencing data.Genome medicine · 2023Article
- Barcoded multiple displacement amplification for high coverage sequencing in spatial genomics.Nature communications · 2023Article
- The end of the beginning: application of single-cell sequencing to chronic lymphocytic leukemia.Blood · 2023Review
- Towards precision medicine in lymphoid malignancies.Journal of internal medicine · 2022Review
- Single-cell RNA sequencing to track novel perspectives in HSC heterogeneity.Stem cell research & therapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 7 institutions in 3 countries.
Lili WangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Jean FanDepartment of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts 02115, USA.
Joshua M FrancisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
George GeorghiouProtein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee DD1 4HN, United Kingdom.
Sarah HergertDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Shuqiang LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Rutendo GambeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Chensheng W ZhouDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Chunxiao YangSuzhou Precision Medicine Scientific Ltd, Suzhou, China, 215006.
Sheng XiaoHarvard Medical School, Boston, Massachusetts 02115, USA.
Paola Dal CinHarvard Medical School, Boston, Massachusetts 02115, USA.
Michaela BowdenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Dylan KotliarSuzhou Precision Medicine Scientific Ltd, Suzhou, China, 215006.
Sachet A ShuklaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Jennifer R BrownDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Donna NeubergBiostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Dario R AlessiProtein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee DD1 4HN, United Kingdom.
Cheng-Zhong ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Peter V KharchenkoDepartment of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts 02115, USA.
Kenneth J LivakFluidigm Corporation, South San Francisco, California 94080, USA.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Dana-Farber Cancer Institute · USBroad Institute · USBrigham and Women's Hospital · USHarvard University · USSuzhou Research Institute · CNUniversity of Dundee · GBFluidigm (United States) · US
Funding
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI DAVIDS, MATTHEW S · 2016 to 2025
$17.0MPersonal tumor neoantigens for immunity against chronic lymphocytic leukemiaR01CA155010 · NCI · DANA-FARBER CANCER INST · PI Catherine Ju-Ying Wu · 2011 to 2026
$9.6M(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemiaR01CA216273 · NCI · DANA-FARBER CANCER INST · PI WANG, LILI, WU, CATHERINE JU-YING · 2017 to 2021
$3.5MITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" TherapieU10CA180861 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D, MARCUCCI, GUIDO · 2014 to 2018
$3.4MStatistical methods for analysis of single-cell variabilityR01HL131768 · NHLBI · HARVARD MEDICAL SCHOOL · PI KHARCHENKO, PETER V · 2015 to 2019
$2.4MThe role of the SF3B1 splicing factor in chronic lymphocytic leukemiaR01HL116452 · NHLBI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2013 to 2017
$2.1MDefining the impact of clonal evolution on chronic lymphocytic leukemiaR01CA182461 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2014 to 2018
$1.8MPost-transplant vaccines to enhance graft-versus-leukemia responsesR01HL103532 · NHLBI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2010 to 2013
$1.7MComputational Analysis of Subclonal Evolution in Chronic Lymphocytic LeukemiaF31CA206236 · NCI · HARVARD MEDICAL SCHOOL · PI FAN, JEAN · 2016 to 2017
$47kMedical Research Council MC_U127070193Medical Research Council MC_UU_12016/2NCI NIH HHS F31 CA206236NCI NIH HHS P01 CA206978NCI NIH HHS R01 CA155010NCI NIH HHS R01 CA182461NCI NIH HHS R01 CA216273NCI NIH HHS U10 CA180861NHLBI NIH HHS R01 HL103532NHLBI NIH HHS R01 HL116452NHLBI NIH HHS R01 HL131768NIGMS NIH HHS T32 GM007753
Abstract
Intra-tumoral genetic heterogeneity has been characterized across cancers by genome sequencing of bulk tumors, including chronic lymphocytic leukemia (CLL). In order to more accurately identify subclones, define phylogenetic relationships, and probe genotype-phenotype relationships, we developed methods for targeted mutation detection in DNA and RNA isolated from thousands of single cells from five CLL samples. By clearly resolving phylogenic relationships, we uncovered mutated
Indexed as
MutationAdultBiomarkers, TumorCase-Control StudiesEvolution, MolecularFemaleHigh-Throughput Nucleotide SequencingHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedSequence Analysis, DNASingle-Cell AnalysisTranscription, GeneticBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.